Image showing sections of cerebral brain organoids derived from pluripotent stem cells.
via Agnieszka Rybak-Wolf, MDC/LifeTime
Hundreds of researchers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare. In a perspective in Nature and the LifeTime Strategic Research Agenda they now present a roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.
The LifeTime initiative, co-coordinated by the Max Delbrück Center of Molecular Medicine in the Helmholtz Association (MDC) in Berlin and the Institut Curie in Paris, has developed a strategy to advance personalized treatment for five major disease classes: cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases. The aim is a new age of personalized, cell-based interceptive medicine for Europe with the potential of improved health outcomes and more cost-effective treatment, resulting in profoundly changing a person’s healthcare experience.
Earlier detection and more effective treatment of diseases
To form a functioning, healthy body, our cells follow developmental paths during which they acquire specific roles in tissues and organs. But when they deviate from their healthy course, they accumulate changes leading to disease which remain undetected until symptoms appear. At this point, medical treatment is often invasive, expensive and inefficient. However, now we have the technologies to capture the molecular makeup of individual cells and to detect the emergence of disease or therapy resistance much earlier.
Using breakthrough single-cell and imaging technologies in combination with artificial intelligence and personalized disease models will allow us to not only predict disease onset earlier, but also to select the most effective therapies for individual patients. Targeting disease-causing cells to intercept disorders before irreparable damage occurs will substantially improve the outlook for many patients and has the potential of saving billions of Euros of disease-related costs in Europe.
A detailed roadmap for implementing LifeTime
The perspective article “The LifeTime initiative and the future of cell-based interceptive medicine in Europe” and the LifeTime Strategic Research Agenda (SRA) explain how these technologies should be rapidly co-developed, transitioned into clinical settings and applied to the five major disease areas. Close interactions between European infrastructures, research institutions, hospitals and industry will be essential to generate, share and analyze LifeTime’s big medical data across European borders. The initiative’s vision advocates ethically responsible research to benefit citizens all across Europe.
According to Professor Nikolaus Rajewsky, scientific director of the Berlin Institute for Medical System Biology at the Max Delbrück Center for Molecular Medicine and coordinator of the LifeTime Initiative, the LifeTime approach is the way into the future: “LifeTime has brought together scientists across fields – from biologists, to clinicians, data scientists, engineers, mathematicians, and physicists – to enable a much improved understanding of molecular mechanisms driving health and disease. Cell-based medicine will allow doctors to diagnose diseases earlier and intercept disorders before irreparable damage has occurred. LifeTime has a unique value proposition that promises to improve the European patient’s health.”
Dr. Geneviève Almouzni, director of research at CNRS, honorary director of the research center from Institut Curie in Paris and co-coordinator of the LifeTime Initiative believes that the future with LifeTime offers major social and economic impact: “By implementing interceptive, cell-based medicine we will be able to considerably improve treatment across many diseases. Patients all over the world will be able to lead longer, healthier lives. The economic impact could be tremendous with billions of Euros saved from productivity gains simply for cancer, and significantly shortened ICU stays for Covid-19. We hope EU leaders will realize we have to invest in the necessary research now.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cell-based interceptive medicine
- Precision medicine tool predicts breast cancer immunotherapy response
New InteractPrint tool analyzes how breast cancer epithelial cells impact cancer-immune interactions, enabling prediction of immune checkpoint inhibition response.
- Evidence-Based Medicine in Managed Care: A Survey of Current and Emerging Strategies
Evidence-based medicine is not a new concept. British epidemiologist Archie Cochrane is regarded as the originator of the concept. His efforts in the mid-1950s to 1960s to categorize studies led ...
- New technique improves T cell-based immunotherapies for solid tumors
"Solid tumors form a microenvironment around themselves that is immunosuppressive," says senior author Peng Wu, Ph.D., a professor in the Department of Molecular Medicine at Scripps Research. "Immune ...
- Stem Cells News
Genetically Modified Pluripotent Stem Cells May Evade Immunological Rejection After Transplantation, Study Shows Jan. 11, 2024 — One of the biggest barriers to regenerative medicine is ...
- Examining the impact of gene-based breeding on agriculture and medicine
A research team has demonstrated that gene-based breeding (GBB) offers a transformative approach to advancing plant and animal breeding, showing remarkable predictability, speed, and ...
Go deeper with Google Headlines on:
Cell-based interceptive medicine
[google_news title=”” keyword=”cell-based interceptive medicine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
LifeTime Initiative
- Midol® Addresses Period Education and Normalization of Menstrual Discomfort with PeriodTalk Initiative in Partnership with Nonprofit PERIOD.
Fifty percent of people with periods reported they did not know what was happening to their body when they first experienced period symptoms and only around 40% of respondents could name the four ...
- Safe Haven Baby Boxes coming to Tupelo, Booneville
City leaders in Tupelo and Booneville recently approved of the installation of a Safe Haven Baby Box at a fire station.
- Why supporters of Washington’s long-term care program are worried
With a looming ballot initiative threatening to upend the finances of Washington’s long-term care benefit, the state is looking at contingency plans.
- Federal Funds Summit seeks maximum funding for Hawaiʻi
Gov. Josh Green, M.D., his Federal Funds Team and the Department of Transportation are hosting a federal funds summit from July 16-18 under the governor’s Investing in Hawai‘i’s Future, a ...
- WA decides: Initiative 2124 to make the state’s long-term care program optional
This article is one in a series looking at statewide initiatives on Washington’s 2024 November ballot. Initiative 2124 would amend the state’s long-term care program, known as WA Cares, so all workers ...
Go deeper with Google Headlines on:
LifeTime initiative
[google_news title=”” keyword=”LifeTime initiative” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]